Physicochemical Properties
| Molecular Formula | C60H96N20O21S2 |
| Molecular Weight | 1497.65564 |
| Exact Mass | 1496.65 |
| CAS # | 37293-17-7 |
| PubChem CID | 9877229 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.53g/cm3 |
| LogP | -8.9 |
| Hydrogen Bond Donor Count | 23 |
| Hydrogen Bond Acceptor Count | 34 |
| Rotatable Bond Count | 44 |
| Heavy Atom Count | 103 |
| Complexity | 2690 |
| Defined Atom Stereocenter Count | 19 |
| SMILES | NCCCNCCCCNCCCNC(C1=CSC(C2=CSC(CCNC([C@@H](NC([C@H]([C@@H]([C@H](NC([C@H]([C@@H](O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(=O)N)[C@@H]3O)C3=CN=CN3)NC(C3N=C([C@@H](NC[C@@H](C(=O)N)N)CC(=O)N)N=C(N)C=3C)=O)=O)C)O)C)=O)[C@H](O)C)=O)=N2)=N1)=O |
| InChi Key | FOUFFVYWFNBHHH-YNGSZULRSA-N |
| InChi Code | InChI=1S/C60H96N20O21S2/c1-25-38(77-51(80-49(25)64)30(17-36(63)84)72-18-29(62)50(65)90)55(94)79-40(46(31-19-69-24-73-31)99-59-48(44(88)42(86)34(20-81)98-59)100-58-45(89)47(101-60(66)96)43(87)35(21-82)97-58)56(95)74-27(3)41(85)26(2)52(91)78-39(28(4)83)54(93)71-16-9-37-75-33(23-102-37)57-76-32(22-103-57)53(92)70-15-8-14-68-12-6-5-11-67-13-7-10-61/h19,22-24,26-30,34-35,39-48,58-59,67-68,72,81-83,85-89H,5-18,20-21,61-62H2,1-4H3,(H2,63,84)(H2,65,90)(H2,66,96)(H,69,73)(H,70,92)(H,71,93)(H,74,95)(H,78,91)(H,79,94)(H2,64,77,80)/t26-,27+,28+,29-,30-,34-,35+,39-,40-,41-,42+,43+,44-,45-,46-,47-,48-,58+,59-/m0/s1 |
| Chemical Name | [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-5-[[(2S,3R)-1-[2-[4-[4-[3-[4-(3-aminopropylamino)butylamino]propylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-4-methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In Eca-109 cells, boanmycin (50-125 μg/mL, 0.5-36 h) can cause apoptosis and stop the cell cycle in the G2/M phase [2]. Boanmycin causes cellular senescence at 6.7 µg/mL for 24 hours [3]. |
| ln Vivo | In BALB/c nude mice, HT-29, Hce-8693, or CT-26 cell tumors can be effectively inhibited from growing by administering boamycin (BAM) via intraperitoneal injection at doses of 10 or 15 mg/kg twice a week for five weeks [1]. |
| Cell Assay |
Cell viability assay [3] Cell Types: human lung fibroblast cell line IMR90, mouse primary osteoblasts (OB) Tested Concentrations: 6.7 µg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Number of positive SA-βgal stained cells in IMR90 cells It was 90% in the OB group, 95%, and 30% in the control group. RT-PCR[3] Cell Types: Mouse primary osteoblasts (OB) Tested Concentrations: 6.7 µg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Expression of the senescence-associated secretory phenotype (SASP) factor IL-6 increased to six-fold. |
| Animal Protocol |
Animal/Disease Models: HT-29 or Hce-8693 cells BALB/c nude mice [1] Doses: 10 or 15 mg/kg Route of Administration: intraperitoneal (ip) injection; twice a week; 5-week Experimental Results: in HT-29 model mice Among them, it can Dramatically inhibit tumor growth by 89% at the dose of 10 mg/kg, 92% at the dose of 15 mg/kg, 90% at the dose of 10 mg/kg, and 90% at the dose of 15 mg/kg. Inhibited by 92%. 15 mg/kg in Hce-8693 model mice. Animal/Disease Models: CT-26 cells BALB/c nude mice [1] Doses: 10 mg/kg Route of Administration: intramuscularinjection; every other day; 10 times Experimental Results: Inhibited the growth of subcutaneoustumors by 88% and inhibited the growth of cecal tumors by 99% . |
| References |
[1]. Y C Deng, et al. Activity of boanmycin against colorectal cancer. World J Gastroenterol. 2001 Feb;7(1):93-7. [2]. Hao Tang, et al. Effect of boanmycin on apoptosis and cell cycle of human esophageal cancer(Eca-109) cells]. Ai Zheng. 2002 Aug;21(8):855-9. [3]. Peng Chen, et al. The chemotherapeutic drug boanmycin induces cell senescence and senescence-associated secretory phenotype factors, thus acquiring the potential to remodel the tumor microenvironment. Anticancer Drugs. 2016 Feb;27(2):84-8. |
| Additional Infomation |
Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer. It was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment. The development of this drug, apparently, was discontinued. Bleomycin A6 has been reported in Streptomyces verticillus with data available. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6677 mL | 3.3385 mL | 6.6771 mL | |
| 5 mM | 0.1335 mL | 0.6677 mL | 1.3354 mL | |
| 10 mM | 0.0668 mL | 0.3339 mL | 0.6677 mL |